AR049405A1 - Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo - Google Patents

Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo

Info

Publication number
AR049405A1
AR049405A1 ARP050102539A ARP050102539A AR049405A1 AR 049405 A1 AR049405 A1 AR 049405A1 AR P050102539 A ARP050102539 A AR P050102539A AR P050102539 A ARP050102539 A AR P050102539A AR 049405 A1 AR049405 A1 AR 049405A1
Authority
AR
Argentina
Prior art keywords
compound
pyridyl
dimethyl
manufacture
pharmaceutical composition
Prior art date
Application number
ARP050102539A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32800053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR049405A1 publication Critical patent/AR049405A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto de dicetopiperazina que tiene la formula (1): en la que R1 es 2-indanilo, R2 es 1-metilpropilo, R3 es un grupo seleccionado entre 2,6-dimetil-3-piridilo o 4,6-dimetil-3-piridilo; R4 representa metilo y R5 representa H o metilo, o, R4 y R5 junto con el átomo de N al que están unidos representan morfolino, y sus derivados farmacéuticamente aceptables. Composicion farmacéutica que comprende al compuesto descrito, junto con uno o más vehículos farmacéuticamente aceptables. Uso del compuesto para la fabricacion de un medicamento para antagonizar los efectos de la oxitocina en el receptor de oxitocina, util para el tratamiento de una o más enfermedades o afecciones seleccionadas entre parto prematuro, dismenorrea, endometriosis e hiperplasia prostática benigna. Procedimientos para la preparacion de dicho compuesto. Reivindicacion 1: Un compuesto de dicetopiperazina caracterizada porque tiene la formula (1): en la que R1 es 2-indanilo, R2 es 1-metilpropilo, R3 es un grupo seleccionado entre 2,6-dimetil-3-piridilo o 4,6-dimetil-3-piridilo; R4 representa metilo y R5 representa H o metilo, o, R4 y R5 junto con el átomo de N al que están unidos representan morfolino, y sus derivados farmacéuticamente aceptables.
ARP050102539A 2004-06-23 2005-06-21 Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo AR049405A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0414093.5A GB0414093D0 (en) 2004-06-23 2004-06-23 Novel compounds

Publications (1)

Publication Number Publication Date
AR049405A1 true AR049405A1 (es) 2006-07-26

Family

ID=32800053

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102539A AR049405A1 (es) 2004-06-23 2005-06-21 Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo

Country Status (30)

Country Link
US (9) US7550462B2 (es)
EP (2) EP2918580A1 (es)
JP (2) JP5405019B2 (es)
KR (1) KR101186447B1 (es)
CN (1) CN1972924B (es)
AR (1) AR049405A1 (es)
AU (1) AU2005256470B2 (es)
BR (1) BRPI0512376A (es)
CA (1) CA2571527C (es)
CY (1) CY1116183T1 (es)
DK (1) DK1758886T3 (es)
ES (1) ES2537801T3 (es)
GB (1) GB0414093D0 (es)
HK (2) HK1106499A1 (es)
HR (1) HRP20150401T1 (es)
HU (1) HUE025869T2 (es)
IL (2) IL179905A0 (es)
MA (1) MA28675B1 (es)
MX (1) MXPA06014545A (es)
MY (1) MY143578A (es)
NO (1) NO338769B1 (es)
NZ (1) NZ551733A (es)
PE (1) PE20060477A1 (es)
PL (1) PL1758886T3 (es)
PT (1) PT1758886E (es)
RU (1) RU2382038C2 (es)
SI (1) SI1758886T1 (es)
TW (1) TWI348466B (es)
WO (1) WO2006000399A1 (es)
ZA (1) ZA200610022B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
ES2397327T3 (es) 2002-06-17 2013-03-06 Thrasos, Inc. Compuestos asociados a un dominio único de TDF y análogos de los mismos
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
SI2497780T1 (sl) 2005-09-20 2015-08-31 Thrasos Innovation, Inc. Spojine, povezane s TDF, in njihovi analogi
JP2013509391A (ja) 2009-10-30 2013-03-14 グラクソ グループ リミテッド (3r,6r)−3−(2,3−ジヒドロ−1h−インデン−2−イル)−1−[(1r)−1−(2,6−ジメチル−3−ピリジニル)−2−(4−モルホリニル)−2−オキソエチル]−6−[(1s)−1−メチルプロピル]−2,5−ピペラジンジオンの新規結晶性形態
HUE058872T2 (hu) 2016-01-04 2022-09-28 ObsEva SA Hidroxipropil-tiazolidin-karboxamid származék alfa-amino-észtere és tokolitikus szer együttes alkalmazása
WO2017203012A1 (en) * 2016-05-27 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Epelsiban for use in the treatment of adenomyosis
EP3487493B1 (en) 2016-07-21 2021-09-01 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
RU2762019C1 (ru) * 2018-05-29 2021-12-14 Као Корпорейшн Способ оценки функциональной способности листа вызывать ощущение комфорта и лист, вызывающий ощущение комфорта
JP2022546716A (ja) 2019-09-03 2022-11-07 オブセヴァ エス.エー. 胚着床を促進し、流産を防止するためのオキシトシンアンタゴニスト投与レジメン
CA3167121A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
DE3830096A1 (de) 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
KR20010034442A (ko) 1998-01-27 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 치환된 옥소아자헤테로사이클릴 인자 Xa 억제제
WO1999038844A1 (en) 1998-01-29 1999-08-05 Aventis Pharmaceuticals Products Inc. Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
BRPI0512376A (pt) 2008-03-11
US20070254888A1 (en) 2007-11-01
US8202864B2 (en) 2012-06-19
US20110152262A1 (en) 2011-06-23
US20100305127A1 (en) 2010-12-02
US20120202811A1 (en) 2012-08-09
CN1972924A (zh) 2007-05-30
SI1758886T1 (sl) 2015-06-30
HRP20150401T1 (hr) 2015-05-08
EP2918580A1 (en) 2015-09-16
EP1758886A1 (en) 2007-03-07
IL237513A0 (en) 2015-04-30
KR101186447B1 (ko) 2012-09-27
JP5405019B2 (ja) 2014-02-05
MA28675B1 (fr) 2007-06-01
AU2005256470A1 (en) 2006-01-05
US7550462B2 (en) 2009-06-23
DK1758886T3 (da) 2015-04-27
CA2571527C (en) 2013-02-26
EP1758886B1 (en) 2015-03-04
TW200616636A (en) 2006-06-01
MY143578A (en) 2011-05-31
US7919492B2 (en) 2011-04-05
PT1758886E (pt) 2015-04-22
NO338769B1 (no) 2016-10-17
PL1758886T3 (pl) 2015-08-31
US20150157640A1 (en) 2015-06-11
US20090247541A1 (en) 2009-10-01
JP2008503534A (ja) 2008-02-07
GB0414093D0 (en) 2004-07-28
CY1116183T1 (el) 2017-02-08
IL179905A0 (en) 2007-05-15
JP2013010790A (ja) 2013-01-17
MXPA06014545A (es) 2007-03-12
AU2005256470B2 (en) 2012-02-02
US9408851B2 (en) 2016-08-09
PE20060477A1 (es) 2006-08-24
JP5503709B2 (ja) 2014-05-28
HK1208669A1 (en) 2016-03-11
US20140235639A1 (en) 2014-08-21
TWI348466B (en) 2011-09-11
WO2006000399A1 (en) 2006-01-05
RU2382038C2 (ru) 2010-02-20
US8742099B2 (en) 2014-06-03
NZ551733A (en) 2010-06-25
CA2571527A1 (en) 2006-01-05
RU2007102274A (ru) 2008-07-27
KR20070031953A (ko) 2007-03-20
ES2537801T3 (es) 2015-06-12
NO20070173L (no) 2007-01-22
ZA200610022B (en) 2008-07-30
HUE025869T2 (en) 2016-05-30
CN1972924B (zh) 2011-07-20
HK1106499A1 (en) 2008-03-14
US20160030442A1 (en) 2016-02-04
US20130253188A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
AR049405A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo
AR049651A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
AR038818A1 (es) Compuesto de piperidina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
UY28578A1 (es) Derivados de amida
AR054612A1 (es) Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes
IL180495A (en) Benzyl triazolone compounds as non-nucleotide reverse transcriptase inhibitors
NO20085077L (no) Nye forbindelser
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
TW200612936A (en) Indole derivatives
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
AR035651A1 (es) Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion
ATE386725T1 (de) Heterocyclylverbindungen
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
ATE233754T1 (de) Diphenyl-piperidin derivate
DK1583538T3 (da) Anvendelse af 3-methozy-pregnenolon til fremstilling af et lægemiddel til behandling af neurodegenerative sygdomme
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR040441A1 (es) Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento
AR057651A1 (es) Derivados n-amida de 8-azabiciclo[3.2.1]oct-3-ilo como antagonistas de ccr1, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas

Legal Events

Date Code Title Description
FC Refusal